Aakash Desai, Assistant Professor and Associate Director of Phase 1 and Precision Oncology Program at the UAB O’Neal Comprehensive Cancer Center, shared a post on LinkedIn:
“HER2-Mutant NSCLC: The TKI vs ADC Debate Heats Up.
With three FDA-approved options now available for HER2-mutant non-small cell lung cancer, the treatment landscape is evolving rapidly. Here’s how they compare.
Key takeaway: Zongertinib’s clean safety profile (17% Grade 3+ AE rate) and high first-line ORR make it a compelling choice – but T-DXd still has mature OS data in 2L and where does TKI post TKI fit?
The sequencing question remains?”
Other articles about HER2-Mutant on OncoDaily.